The ABPI has warned that “there a range of things outside of our control”.
News
Bluebird’s Zynteglo kicks off first Amsterdam CHMP recommendations
The European Medicines Agency’s CHMP positive opinions are sparse this time around.
J&J submits sNDA for Invokana after premature end to clinical trial
If approved, the drug will be the only therapy in nearly 20 years to reduce the risk of end-stage kidney disease.
Boots tests ‘behavioural nudge theory’ for medication adherence
The study found that patients warned of adverse consequences to their own health of skipping doses were more likely to adhere.
NICE backs PredictImmune’s IBD prognosis test
The CE-marked prognostic test for guiding treatment options uses a gene expression “signature”.
BMS signs deal with Concerto HealthAI
The partnership will give the American pharma giant access to Concerto’s eurekaHealth AI insights platform.
AstraZeneca and Daiichi sign $6.9bn cancer drug deal
The collaboration is aligned with AstraZeneca’s science-led strategy in oncology.
New pharma Azadyne raises £1.5m for autoimmune disease treatment
The Trinity College spin-off has completed a £1.5-million funding round for its autoimmune treatments.
NHS aims for one link worker per primary care network from July
The social prescription plan aims to bring about the major shift in perspective needed.
AZ’ Imfinzi to be funded for NHS use via CDF
AstraZeneca’s PD-L1 inhibitor Imfinzi will be made available on the NHS in England immediately for patients with locally advanced unresectable non-small-cell lung cancer.
Number of prescription rises but cost falls again
Latest data from NHS Digital shows an increase in the number of prescription items dispensed in the community, but a drop in their cost to the NHS.
Celgene resubmits MS drug, ozanimod, to FDA
A filing for ozanimod was initially rejected by the US regulator in February 2017.
Phase III results move Aimmune’s peanut allergy drug closer to EU market
Aimmune to file peanut allergy drug in Europe based on Phase III data showing an improvement in peanut tolerance.
Cancer immunotherapy alliance formed by CR UK, Lifearc and Ono Pharma Form
Cancer Research UK, LifeArc and Ono Pharmaceutical have formed a multi-million-pound drug discovery alliance.
Novartis’ MS drug gets FDA approval
The FDA has approved Novartis’ multiple sclerosis drug, Mayzent.
